

Index

A

Age-standardized rates, 113
Airseal, 101
American Urology Association
 guidelines, 119
Analgesia use, 65
Antibiotic prophylaxis, 153, 154
Antiplatelet and anticoagulant therapy, 155

B

Biopsy approaches, 141
Bladder cancer, 2, 23, 29
Bleeding, 154

C

Canadian Urology Association
 guidelines, 120
Carcinoma in situ, 119
Chromatin modifier mutations, 45
Chromatin modifiers, 47
Circumcision and hygiene, 132
Clamping techniques, 100
Clear cell urothelial carcinoma, 6
Cognitive targeting, 150
Combination therapies, 176
Complications, 123
Concomitant diseases, 65
Cyclical quality assurance, 187

D

DaVinci surgical system, 102
Demography, 25

Diagnosis, 141
Diagnostic and therapeutic utility, 32
Diagnostic biomarkers, 35
Diet, 64
Differentiation, 1
Digital rectal examination, 142
Disease profile, 199
DNA methylation, 47

E

Education, 133
Endorectal ultrasound transducer, 145
Endoscopic ultrasound, 102
Epidemiology, 107, 131
Epidrugs, 54
Epigenetic deregulations, 48
Epigenetic landscape, 48
Epigenetic regulation, 45
Epigenetic therapy, 53
Equipment, 145
Erectile dysfunction, 155
ERK inhibition, 178
Etiology of bladder Cancer, 23
Etiology of renal cell carcinoma, 61
European Association of Urology
 guidelines, 120

F

Family history, 199
Fertility outcomes, 125
Frozen section, 123
Functional outcomes, 50

Funnel plot, 190
Future treatment strategies, 169

G

Gender, 25, 63, 65
Genetic factors, 63
Genetics, 25
Genomic and molecular applications, 175
Germ cell tumors, 108
Germline genetics, 199
Germline single nucleotide polymorphisms, 205
Giant cell urothelial carcinoma, 6
Ginsburg protocol, 148
Glandular differentiation, 7
Glycogen-rich urothelial carcinoma, 6

H

Hereditary, 25
Histologic subtypes, 2
Hormonal outcomes, 126
Human papilloma virus, 132
Hypertension, 64

I

ICG-fluorescence, 100
Imaging, 174
Immunoprofile, 15
Improving prostate cancer care, 185
In-bore magnetic resonance image-guided biopsies, 151
Indocyanine green, 100
Infection in transrectal biopsies, 152
Invasive urothelial carcinoma, 1, 8
Inverted urothelial papilloma, 15

J

JAK3, 5
JmJc domain, 51

K

Keratinization, 7
Kidney disease, 65

L

Leydig cell, 108
Lipid-rich urothelial carcinoma, 6
Lymphoepithelioma-like urothelial carcinoma, 5
Lynch syndrome, 204

M

Malignant germ cell tumors, 121
Malignant potential, 16
Metastamirs, 31, 71
Metastasis-promoting miRNAs, 32, 73
Metastasis-suppressing miRNAs, 33, 74
Metastatic kidney cancer, 71
Metastatic phenotype, 29
Microcystic urothelial carcinoma, 5
Micropapillary urothelial carcinoma, 3
MicroRNA, 29, 71
Modern care, 174
Molecular biology, 169
Molecular classification, 8
Mortality, 25, 155
MRI, 150

N

Needle tract seeding, 155
Neoplastic transformation, 49

Nephron sparing surgery, 97
Nested urothelial carcinoma, 4
Neuroendocrine differentiation, 8
Neuroendocrine prostate cancer, 178
Non-antibiotic measures in transrectal biopsy, 154
Non-coding RNAs, 49
Non-invasive high grade, 18
Non-invasive low grade, 17
Nonseminomas, 108

O

Obesity, 26, 64
Occupational exposure, 26
Oncological outcomes, 125
Organ sparing surgery, 117, 124
Outcomes, 124

P

Papillary urothelial neoplasms, 13
Parasagittal view, 146
Partial nephrectomy, 95
Partial orchidectomy, 118, 123
Patient eligibility criteria, 119, 120
Pediatric patient, 121
Penile cancer, 131, 133
Perineum, 144
Permanent seed brachytherapy, 173
PET imaging, 174
Phimosis, 132
Plasmacytoid urothelial carcinoma, 4
Post prostatectomy, 173
Pre-operative assessment, 122
Procedural analgesia, 144
Procedural complications, 152
Procedure, 145
Process improvements, 171

Prognostic indicators, 36
Prostate anatomy, 143
Prostate biopsy principles, 143
Prostate biopsy schemes, 147
Prostate cancer, 141, 169, 199

Q

Quality assurance programs, 185
Quantification, 19

R

Radiation oncology, 169
Radiation therapy, 173
Radical orchidectomy, 118
Radiotherapy, 119
Renal cell carcinoma, 62, 71
Retroperitoneal approach, 98
Risk factors, 108, 132
Risk-adjusted cumulative sum, 189
Risks, 66
Robot-assisted radical prostatectomy, 190
Robotic biopsies, 151
Robotic retroperitoneal partial nephrectomy, 95
Robotic technology, 102

S

Schistosomiasis infection, 26
Screening, 199
Seminomas, 108
Sertoli cell tumors, 108
Small renal mass, 96
Smoking, 26, 64, 66, 133
Socio-economic status, 133
Squamous differentiation, 6, 7

Statistical quality assurance, 187
Stromal tumors, 108
Subtypes, 1
Surgical procedure, 121
Surgical technique, 122
Systematic biopsies, 147

T

Targeted prostate biopsies, 149
Targeting methodology, 151
Testicular cancer, 107, 117
TilePro, 102
Transitional cell carcinoma, 24
Transperineal biopsies, 144
Transperineal biopsy schemes, 148
Transperineal freehand technique, 149
Transperineal template mapping
 biopsy, 148
Transperitoneal approach, 98
Transrectal extended systematic
 biopsy, 147
Transrectal saturation biopsy, 147
Transrectal ultrasound, 144
Transrectal ultrasound-mpMRI fusion
 biopsies, 150
Transurethral resection of bladder
 tumor, 24
Treatment response, 35
Trophoblastic differentiation, 8
TURBT, 24

U

Ultrasound targeted, 149
Upper tract urothelial carcinoma, 37,
 61, 65
Urinary retention, 154
Urothelial carcinoma, 1
Urothelial papilloma, 14

V

Variants, 2
Vimentin, 34
von Hippel Lindau, 63

W

WDR62, 33
WHO/ISUP histologic grade, 19
Wnt/ β -catenin, 34

X

XIAP, 77

Y

YAP1, 77
YWHAZ, 77

Z

ZEB2, 33
Zonal anatomy, 143